Signalrx Pharmaceuticals Inc Profile last edited on: 7/20/23
CAGE: 6SFS2
UEI: JXNMAWC5BY65
Business Identifier: Cancer drug development based on the inhibition of PI3 kinase 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 52
County: San Diego
Congr. District: 52
County: San Diego
Public Profile
A clinical stage company with facilities and operations in San Diego, CA and in Omaha, NE, SignalRx Pharmaceuticals is structured around development effective anti=cancer treatments inducing the immune system to attack cancer while blocking the most important and critical cell signaling pathways that cancer cells use to proliferate, migrate, metastasize, and recruit a blood supply. Efforts of the principals are aimed at combining the maximum anticancer activity into the firm's drugs by selectively inhibiting as many important cancer targets as possible in a well-tolerated non-toxic manner where the immune system machinery of the patient is engaged to achieve maximum synergistic anticancer effects.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2019 | 1 | NIH | $299,888 | |
| Project Title: Overcoming Btk Inhibitor Resistance In B-Cell Malignancies | ||||
| 2018 | 1 | NIH | $299,738 | |
| Project Title: Discovery of Novel Cdk4/6-Pi3k-Brd4 Inhibitor Srx3177 for Augmented Anti-Cancer Activity | ||||
| 2018 | 2 | NIH | $2,177,270 | |
| Project Title: Maximal MYC Control Using Dual PI-3K/BRD4 (Kinase/Epigenetic) Inhibitors | ||||
| 2016 | 1 | NIH | $299,738 | |
| Project Title: Maximizing Cancer Synthetic Lethality Using Dual Pi-3k/Parp Inhibitors | ||||
Key People / Management
Donald Durden -- Founder and CEO
Joseph R Garlich -- CSO
Guillermo A Morales -- VP and Director of Research
Joseph R Garlich -- CSO
Guillermo A Morales -- VP and Director of Research
Company News
There are no news available.
